Lantheus Holdings, Inc. is a radiopharmaceutical company that develops, manufactures, and commercializes diagnostic and therapeutic products. Its business is organized into three segments: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Key commercial products include PYLARIFY for prostate cancer imaging, DEFINITY for echocardiography, RELISTOR for opioid-induced constipation, and Neuraceq for Alzheimer’s disease diagnosis. The company also holds clinical-stage assets such as LNTH-2401, LNTH-2402, LNTH-2403, and LNTH-2404, as well as NAV-4694 for Alzheimer’s imaging. Lantheus serves healthcare professionals including cardiologists, oncologists, and nuclear medicine physicians, selling primarily to hospitals, independent imaging centers, and government facilities in the United States. Internationally, it operates through direct and third-party distribution in Europe, Canada, Australia, Asia-Pacific, Central America, and South America. The company was founded in 1956 as New England Nuclear and has since undergone several ownership changes, including acquisitions by DuPont and Bristol-Myers Squibb, before launching as Lantheus Medical Imaging. Recent strategic moves include the acquisition of Evergreen Theragnostics for CDMO services and radiotherapeutics, and Life Molecular Imaging for Alzheimer’s diagnostics, which was renamed Lantheus Biosciences Ltd. in 2026.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Drug Manufacturers - General Homepage lantheus.com
Sector Healthcare IR page investor.lantheus.com
Tags
radiopharmaceuticals, pet imaging, radiotherapeutics, alzheimer's diagnostics, prostate cancer imaging, echocardiography, cdmo services, precision medicine, biomarkers, oncology, PYLARIFY, DEFINITY, RELISTOR, Neuraceq, TechneLite, NEUROLITE, Xenon Xe-133 Gas, Cardiolite, LNTH-2401, LNTH-2402, LNTH-2403, LNTH-2404, NAV-4694, Flyrcado, PYLARIFY AI, Evergreen Theragnostics, Life Molecular Imaging, Lantheus Biosciences Ltd., Meilleur Technologies, Cerveau Technologies, POINT Biopharma, Radiopharm Theranostics Limited
Press page investor.lantheus.com/news-events/press-releases

Metrics

Valuation  
Market cap $ 6.507B
Market cap (USD) $ 6.507B
P/E 24.28
PEG 0.24
P/BV 4.80
P/S 4.16
P/OCF 15.89
P/FCF 18.66
Dividend yield —
Turnover / mcap —
Returns  
ROE 21.4%
ROI 14.1%
ROIC 13.9%
Profit margin 15.2%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) 102.6%
Quality  
Profitable Yes
Margin expanding No
Buying back stock Yes
Diluting (TTM) No
Debt/Equity 52.2%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 82
Quality score 33.3%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014
Revenue 1.542B 1.534B 1.296B 935.061M 425.208M 339.41M 347.337M 343.374M 331.378M 301.853M 293.461M 301.6M
Net profit 233.559M 312.442M 326.661M 28.067M -71.279M -13.473M 31.667M 40.518M 123.385M 26.762M -14.746M -3.561M
Free cash flow 348.639M 465.125M 259.915M 21.781M 41.776M 3.922M 58.323M 41.061M 37.234M 42.244M 8.611M 3.453M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014
Share price 66.55 89.46 62 50.96 28.89 13.49 20.51 15.65 20.45 8.6 3.38 —
Price performance 12m -0.26 0.44 0.22 0.76 1.14 -0.34 0.31 -0.23 1.38 1.54 — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 36.8M 40.3M 43.8M 43.5M 54M 89.3M 213M 284M 321M 359M
↳ YoY growth -1.3% +9.3% +8.7% -0.5% +24.1% +65.4% +138.9% +33.2% +13.0% +11.6%
↳ 5y CAGR +0.9% +7.7% +19.4% +39.6% +45.4% +49.1% +46.0%
Borrowings, current (USD) 3.65M 2.75M 2.75M 10.1M 20.7M 11.6M 354,000 823,000 974,000 738,000
Borrowings, non-current (USD) 274M 265M 264M 184M 198M 163M 558M 562M 565M 569M
Lease liabilities (USD) — — — 1.33M 19.2M 18.8M 28.2M 57.8M 56.7M 55.1M
Cash and deposits (USD) 51.2M 76.3M 113M 92.9M 79.6M 98.5M 416M 714M 913M 359M
Intangible assets (USD) 15.1M 11.8M 9.13M 7.34M 376M 349M 315M 152M 162M 723M
Right-of-use assets (USD) — — — 935,000 18.4M 8.79M 19M 45.3M 36.1M 31M
Net debt (borrowings + leases - cash) (USD) 227M 192M 153M 102M 158M 95.1M 171M -93.4M -290M 265M
Cash flow detail
Operating cash flow (USD) 49.6M 54.8M 61.2M 80.4M 16.4M 53.9M 282M 305M 545M 390M
Purchases of property, plant and equipment (USD) -7.4M -17.5M -20.1M -22.1M -12.5M -12.1M -260M -45.3M — —
Purchases of intangible assets (USD) — — — — — — 0.00 0.00 -28M 0.00
Change in receivables (cash effect) (USD) -1.06M -3.41M -3.99M 156,000 -7.46M -33.1M -128M -68.6M -37.7M -17.9M
Change in inventories (cash effect) (USD) -3.63M -9.62M -8.69M 1.99M -8.46M -3.55M -7.51M -36.2M -2.67M -9.37M
Change in payables (cash effect) (USD) 5.7M 604,000 -2.89M 3.23M -4.22M 5.43M 301,000 17.2M -8.8M -2.49M
Share buybacks (cash effect) (USD) — — — — 0.00 0.00 -75M 0.00 -100M -300M
Interest paid (cash effect) (USD) -24.4M -16.7M -15.9M -12.3M -9.37M -6.28M -5.06M -15.4M -15.1M -15.1M
Income taxes paid (cash effect) (USD) -265,000 -106,000 -90,000 -274,000 -340,000 -215,000 -54M -152M -154M -69M
Share-based compensation (USD) 2.52M 5.93M 8.72M 12.5M 14.1M 15.9M 29.3M 50.5M 76.4M 85.6M
Operating cash flow before change in receivables (USD) 50.7M 58.2M 65.2M 80.2M 23.9M 87M 410M 374M 582M 408M
Free cash flow (OCF - PPE - intangibles) (USD) 42.2M 37.2M 41.1M 58.3M 3.92M 41.8M 21.8M 260M — —
Income detail
Research and development expense (USD) 12.2M 18.1M 17.1M 20M 32.8M 45M 312M 77.7M 168M 177M
↳ 5y CAGR -10.9% +7.9% +18.0% +29.8% +76.6% +35.4% +53.0% +40.2%
Total comprehensive income (USD) 27.8M 123M 40.4M 31.8M -14.6M -69.7M 27.3M 327M 312M 234M
Comprehensive income to owners (USD) 27.8M 123M 40.4M 31.8M -14.6M -69.7M 27.3M 327M 312M 234M
Provision for credit losses (USD) 53,000 136,000 321,000 146,000 — — — — — —
Credit cost ratio (credit losses / average receivables) (%) 0.1% 0.4% 0.8% 0.3% — — — — — —
Reported Feb 23, 2017 Feb 26, 2018 Feb 20, 2019 Feb 25, 2020 Feb 23, 2023 Feb 23, 2023 Feb 26, 2025 Feb 26, 2025 Feb 26, 2025 Feb 26, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Lantheus Holdings, Inc. — Other Events Bull 0 Bear 0 M&A

On November 8, 2026, Lantheus Holdings, Inc., a Delaware corporation (“Lantheus” or the “Company”), entered into a definitive agreement with PharmaLogic Holdings Corp. (“PharmaLogic”) to sell its contract development and manufacturing organization (“CDMO”) business and Springfield, New Jersey manufacturing facility to PharmaLogic. The sale is subject to customary closing conditions and the Company will provide certain transition services to PharmaLogic immediately following the closing. In addition, the parties will enter into a long-term supply agreement under which PharmaLogic’s therapeutic CDMO franchise, Agilera, will manufacture lutetium Lu 177 dotatate for the Company. Forward-Looking Statements This Current Report on Form 8-K contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that are subject to risks and uncertainties and are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.


Nov 5, 2026

PDF Version

  • Worldwide revenue of $389.9 million in the third quarter of 2026
  • GAAP fully diluted earnings per share of $0.33, compared to $0.41 in the third quarter of 2025
  • Adjusted fully diluted earnings per share of $1.68, compared to $1.27 in the third quarter of 2025
  • FDA approves TAUKLARIFY™ (florquinitau F-18 injection); an F-18-labeled tau PET imaging agent for the evaluation of adults with cognitive impairment being assessed for Alzheimer’s disease
  • FDA grants final approval for BRAVNETSA™ (lutetium Lu 177 dotatate); the only radiopharmaceutical the FDA has determined to be bioequivalent and therapeutically equivalent to LUTATHERA® for the treatment of adults with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
  • Announced on August 3, 2026 that the Company has entered into a definitive agreement to merge with Curium under which Curium US Holdings LLC will acquire all outstanding shares of the Company in an all-cash transaction that represents a total transaction value of up to approximately $8.0 billion

BEDFORD, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (Lantheus or the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today reported financial results for its third quarter ended September 30, 2026.

In addition, and as previously announced, Lantheus entered into a definitive agreement on August 3, 2026 to merge with Curium under which Curium US Holdings LLC will acquire all outstanding shares of Lantheus for $102.50 per share in cash at closing, plus non-transferable Contingent Value Rights (“CVRs”) providing for up to $12.00 per share in potential additional cash payments, subject to achievement of specified commercial milestones for Lantheus’ products through 2030. The transaction represents a total per share consideration of up to $114.50 and a total transaction value of up to approximately $8.0 billion. Together, Curium and Lantheus are positioned to create a radiopharmaceutical company spanning diagnostics and therapeutics, with the infrastructure and capabilities to serve patients in more than 70 countries. The Board of Directors of Lantheus has unanimously approved the transaction. Additional information regarding the transaction is available in the Company’s Current Report on Form 8-K filed with the SEC on August 4, 2026.

In connection with the pending transaction, Lantheus is suspending its previously issued full year 2026 financial guidance and will not be hosting a conference call in connection with its third quarter 2026 results.

Summary Financial Results

Three Months Ended September 30,
(in millions, except per share data - unaudited) 2026 2025 % Change
Worldwide revenue $ 389.9 $ 384.0 1.5 %
GAAP net income $ 22.4 $ 27.8 (19.4 %)
GAAP fully diluted earnings per share $ 0.33 $ 0.41 (19.5 %)
Adjusted net income (non-GAAP) $ 115.1 $ 85.7 34.3 %
Adjusted fully diluted earnings per share (non-GAAP) $ 1.68 $ 1.27 32.3 %

**
Third Quarter 2026**

  • Worldwide revenue increased 1.5% to $389.9 million compared to the same period in 2025.
  • Sales of PYLARIFY were $238.9 million, a decrease of 0.7%.
  • Sales of Neuraceq were $45.6 million, an increase of 123.0%.
  • Sales of DEFINITY were $85.7 million, an increase of 4.8%.
  • Operating income decreased 26.2% to $32.2 million. Adjusted operating income (non-GAAP) increased 28.1% to $153.2 million.
  • Fully diluted earnings per share decreased 19.5% to $0.33, compared to fully diluted earnings per share of $0.41 in the prior year period. Adjusted fully diluted earnings per share (non-GAAP) increased 32.3% to $1.68, compared to $1.27 in the prior year period.
  • Net cash provided by operating activities and free cash flow were $102.0 million and $99.9 million, respectively.

Balance Sheet

  • At September 30, 2026, the Company's cash and cash equivalents were $683.6 million, compared to $359.1 million at December 31, 2025.
  • The Company currently has access to up to $750.0 million from a revolving line of credit.

Recent Business Highlights

  • Received CMS Transitional Pass-Through payment status and a permanent HCPCS code, each effective October 1, 2026, for PYLARIFY® TruVu™ (piflufolastat F18), supporting the Company’s previously announced phased geographic commercial launch.
  • Received FDA approval for TAUKLARIFY (florquinitau F-18 injection), an F-18-labeled tau PET imaging agent for the evaluation of adults with cognitive impairment being assessed for Alzheimer’s disease. The Company intends to continue supporting Alzheimer’s disease therapeutic programs through its Pharma Solutions business while assessing the appropriate path toward broader commercial availability.
  • Received final FDA approval for BRAVNETSA (lutetium Lu 177 dotatate), the only radiopharmaceutical the FDA has determined to be bioequivalent and therapeutically equivalent to LUTATHERA® for the treatment of adults with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors; the Company is preparing for a thoughtful commercial launch to support reliable supply and broad patient access.
  • Dosed the first patient in the SPARROW study, a Phase 2/3 registrational trial evaluating LNTH-2401, the Company’s investigational GRPR-targeted PET imaging agent for prostate cancer; the Phase 3 portion is expected to enroll approximately 400 participants and evaluate diagnostic performance, safety and tolerability.

About Lantheus

Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices in New Jersey, Canada, Germany, Switzerland, Sweden and the United Kingdom, Lantheus has been providing radiopharmaceutical solutions for 70 years. For more information, visit www.lantheus.com.

Internet Posting of Information

The Company routinely posts information that may be important to investors in the “Investors” section of its website at www.lantheus.com. The Company encourages investors and potential investors to consult its website regularly for important information about the Company.

Non-GAAP Financial Measures

The Company uses non-GAAP financial measures, such as adjusted net income and its line components; adjusted fully diluted net income per share; adjusted operating income, and free cash flow. The Company’s management believes that the presentation of these measures provides useful information to investors. These measures may assist investors in evaluating the Company’s operations, period over period. However, these measures may exclude items that may be highly variable, difficult to predict and of a size that could have a substantial impact on the Company’s reported results of operations for a particular period. Management uses these and other non-GAAP measures internally for evaluation of the performance of the business, including the evaluation of results relative to employee performance compensation targets. Investors should consider these non-GAAP measures only as a supplement to, not as a substitute for or as superior to, measures of financial performance prepared in accordance with GAAP.

S****afe Harbor for Forward-Looking and Cautionary Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that are subject to risks and uncertainties and are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements may be identified by their use of terms such as “advance,” “believe,” “continue,” “could,” “driving,” “expect,” “guidance,” “maintain,” “may,” “on track,” “plan,” “potential,” “predict,” “progress,” “should,” “target,” “will,” “would” and other similar terms, or by express or implied discussions regarding the pending merger with Curium (the “Merger”). Such forward-looking statements include our plans to successfully execute on the commercialization of marketed products, ensure launch readiness for new products, advance a focused late-stage pipeline, and allocate capital thoughtfully, and our focus mainly on our radiodiagnostic business and pursuing value-maximizing alternatives for our radiotherapeutic assets, and are based upon current plans, estimates and expectations that are subject to risks and uncertainties that could cause actual results to materially differ from those described in the forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation that such plans, estimates and expectations will be achieved. Readers are cautioned not to place undue reliance on the forward-looking statements contained herein, which speak only as of the date hereof. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law. Risks and uncertainties that could cause our actual results to materially differ from those described in the forward-looking statements include: (i) continued market expansion, penetration and reimbursement for our established commercial products, particularly PYLARIFY, DEFINITY and Neuraceq, in a competitive environment and our ability to clinically and commercially differentiate our products; (ii) our ability to complete the technology transfer across our positron emission tomography (“PET”) manufacturing facilities (“PMF”) network for PYLARIFY TruVu, the new formulation of our F-18 prostate-specific membrane antigen (“PSMA”) PET imaging agent approved by the U.S. Food and Drug Administration (“FDA”) on March 6, 2026, to obtain FDA approval for each PMF to manufacture PYLARIFY TruVu, to maintain adequate coverage and payment for PYLARIFY TruVu, including the transitional pass-through payment status (“TPT Status”) granted by the Centers for Medicare & Medicaid Services, as announced on September 30, 2026, to have payers add Healthcare Common Procedure Coding System (“HCPCS”) code for PYLARIFY TruVu effective October 1, 2026 to their systems on a timely basis and to have customers adopt PYLARIFY TruVu; (iii) the availability of raw materials, key components, equipment, manufacturing time slots, either used in the production of our products and product candidates, or by customers of our products and product candidates, including, but not limited to PET scanners for PYLARIFY, PYLARIFY TruVu, Neuraceq, TAUKLARIFY, LNTH-2501 and NAV-4694; (iv) our ability to have third parties manufacture our products and product candidates and our ability to manufacture DEFINITY in our in-house manufacturing facility, in amounts and at the times needed; (v) our ability to satisfy our obligations under our existing clinical development partnerships using Neuraceq, MK-6240 or NAV-4694 and other assets as a research tool and under the license agreements through which we have rights to those assets, to support TAUKLARIFY (florquinitau F-18 injection), also referred to as MK-6240, which was approved by the FDA on August 14, 2026, including through our Pharma Solutions business, and to determine an appropriate path and timing toward its broader commercial availability, and to further develop and commercialize NAV-4694 as an approved product; (vi) our ability to continue to successfully integrate acquisitions, including of Lantheus Biosciences, which could be impacted by unforeseen expenses related to integration activities, the potential for unforeseen liabilities within that business, the ability to integrate disparate information technology systems, retain key talent and create a merged corporate culture that successfully realizes the full potential of the combined organization; (vii) our ability to obtain FDA approval for LNTH-2501, our investigational kit for the preparation of Gallium-68 edotreotide injection, which has been studied for use in conjunction with a PET scan to stage and localize neuroendocrine tumors in adult and pediatric patients, including satisfactorily resolving certain unresolved third-party facility inspection-related conditions identified in the Complete Response Letter issued by the FDA on June 26, 2026 and obtaining approval of a resubmitted new drug application, and to successfully commercialize LNTH-2501, if approved; (viii) the timing, execution and success of our planned commercialization of BRAVNETSA (lutetium Lu 177 dotatate), previously known as PNT2003, which received final FDA approval on September 22, 2026, including in light of competing lutetium Lu 177 dotatate products, our ability to successfully defend the favorable U.S. District Court ruling invalidating all patents asserted in the related Hatch-Waxman litigation, which is currently on appeal before the U.S. Court of Appeals for the Federal Circuit, and our dependence on POINT Biopharma Global Inc. to manufacture and supply BRAVNETSA; (ix) the cost, efforts and timing for clinical development, manufacturing, regulatory approval, adequate coding, coverage and payment and successful commercialization of our newly approved products, product candidates and new clinical applications and territories for our products, in each case, that we or our strategic partners may undertake, including the SPARROW Phase 2/3 registrational trial of LNTH-2401, and the risk of further impairment of our in-process research and development assets; (x) the timing, execution, and success of our strategic program to simplify and streamline our operations so we can focus mainly on our radiodiagnostic business and pursue value-maximizing alternatives for our radiotherapeutic assets; (xi) our ability to identify opportunities to collaborate with strategic partners and to acquire or in-license additional product opportunities in oncology, neurology and other strategic areas and continue to grow and advance our pipeline of products, subject to the restrictions on the conduct of our business under the Agreement and Plan of Merger, dated as of August 3, 2026 (the “Merger Agreement”), by and among us, Curium US Holdings LLC (the “Parent”), and Coco Merger Sub Inc.; (xii) the timing and outcome of the actions filed against us by alleged stockholders, and of demands or litigation relating to the transactions contemplated by the Merger Agreement; (xiii) the effect that changes to management could have on our business; (xiv) our ability and the ability of the Parent to complete the transactions contemplated by the Merger Agreement, including the parties’ ability to satisfy the remaining closing conditions in the agreement, including the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (which was extended on October 21, 2026 by the Federal Trade Commission), and the receipt of other required antitrust and foreign direct investment approvals; (xv) statements about the expected time frame for completing the proposed Merger; (xvi) our and the Parent’s beliefs and expectations and statements about the benefits sought to be achieved by the proposed Merger; (xvii) the potential effects of the proposed Merger on us and the Parent, including on our relationships with customers, suppliers and employees, and the costs we have incurred and will incur in connection with the proposed Merger whether or not it is completed; (xviii) the possibility of any termination of the Merger Agreement, including in circumstances that would require us to pay a termination fee; (xix) whether any payments will be made under the contingent value rights to be issued in the proposed Merger; and (xx) the risks and uncertainties discussed in our filings with the Securities and Exchange Commission (including those described in the Risk Factors section in our Annual Reports on Form 10-K and our Quarterly Reports on Form 10-Q). 

- Tables Follow -

Lantheus Holdings, Inc. Consolidated Statements of Operations (in thousands, except per share data – unaudited)
Three Months Ended September 30, Nine Months Ended September 30,
2026 2025 2026 2025
Revenues $ 389,913 $ 384,014 $ 1,155,426 $ 1,134,823
Cost of goods sold 146,501 161,648 439,237 433,746
Gross profit 243,412 222,366 716,189 701,077
Operating expenses
Sales and marketing 48,059 48,828 183,548 132,372
General and administrative 70,383 81,898 148,549 205,229
Research and development 92,764 48,025 170,345 129,828
Total operating expenses 211,206 178,751 502,442 467,429
Operating income 32,206 43,615 213,747 233,648
Interest expense 4,940 4,950 14,719 14,671
Net loss (gain) on investment in equity securities 12,164 (1,160 ) 6,795 (871 )
Loss (gain) on sale of business, net of transaction costs 83 — (59,444 ) —
Other income, net (6,758 ) (2,556 ) (20,330 ) (23,579 )
Income before income taxes 21,777 42,381 272,007 243,427
Income tax (benefit) expense (594 ) 14,610 56,190 63,956
Net income $ 22,371 $ 27,771 $ 215,817 $ 179,471
Net income per common share:
Basic $ 0.34 $ 0.41 $ 3.32 $ 2.63
Diluted $ 0.33 $ 0.41 $ 3.21 $ 2.60
Weighted average common shares outstanding:
Basic 65,297 67,230 65,066 68,132
Diluted 68,413 67,663 67,137 69,038
Lantheus Holdings, Inc. ****Consolidated Revenues Analysis (in thousands, except percent data – unaudited)
Three Months Ended Nine Months Ended
September 30, September 30,
2026 2025 Change $ Change % 2026 2025 Change $ Change %
PYLARIFY $ 238,930 $ 240,616 $ (1,686 ) (0.7 )% $ 720,220 $ 748,912 $ (28,692 ) (3.8 )%
Total oncology 238,930 240,616 (1,686 ) (0.7 )% 720,220 748,912 (28,692 ) (3.8 )%
Neuraceq 45,577 20,442 25,135 123.0 % 120,632 20,442 100,190 490.1 %
Total neurology 45,577 20,442 25,135 123.0 % 120,632 20,442 100,190 490.1 %
DEFINITY 85,673 81,785 3,888 4.8 % 258,579 244,935 13,644 5.6 %
Total cardiology 85,673 81,785 3,888 4.8 % 258,579 244,935 13,644 5.6 %
Strategic partnerships and other 19,733 13,705 6,028 44.0 % 55,995 36,042 19,953 55.4 %
SPECT — 27,466 (27,466 ) (100.0 )% — 84,492 (84,492 ) (100.0 )%
Total revenues $ 389,913 $ 384,014 $ 5,899 1.5 % $ 1,155,426 $ 1,134,823 $ 20,603 1.8 %
Lantheus Holdings, Inc. Reconciliation of GAAP to Non-GAAP Financial Measures (in thousands, except per share and percent data – unaudited)
Three Months Ended September 30, Nine Months Ended September 30,
2026 2025 2026 2025
Net income $ 22,371 $ 27,771 $ 215,817 $ 179,471
Stock and incentive plan compensation 21,876 24,501 57,925 68,020
Amortization of acquired intangible assets 16,723 14,639 50,169 30,626
Impairment of intangible assets 31,000 — 31,000 —
Contingent consideration fair value adjustments 3,169 982 (28,586 ) 982
Non-recurring fees 7 — 9,292 2,633
Loss (gain) on sale of business, net of transaction costs 83 — (59,444 ) —
Strategic collaboration and license costs (121 ) 860 116 16,273
Net loss (gain) on investment in equity securities 12,164 (1,116 ) 6,795 (785 )
Acquisition, integration and divestiture-related items 46,941 34,973 50,044 62,645
Other (514 ) (16 ) 32,617 (3,170 )
Income tax effect of non-GAAP adjustments(a) (38,625 ) (16,888 ) (49,924 ) (50,890 )
Adjusted net income $ 115,074 $ 85,706 $ 315,821 $ 305,805
Adjusted net income, as a percentage of revenues 29.5 % 22.3 % 27.3 % 26.9 %
Three Months Ended September 30, Nine Months Ended September 30,
2026 2025 2026 2025
Net income per share - diluted $ 0.33 $ 0.41 $ 3.21 $ 2.60
Stock and incentive plan compensation 0.32 0.36 0.86 0.99
Amortization of acquired intangible assets 0.24 0.22 0.75 0.44
Impairment of intangible assets 0.45 — 0.46 —
Contingent consideration fair value adjustments 0.05 0.01 (0.43 ) 0.01
Non-recurring fees 0.00 — 0.14 0.04
Loss (gain) on sale of business, net of transaction costs 0.00 — (0.89 ) —
Strategic collaboration and license costs (0.00 ) 0.01 0.00 0.24
Net loss (gain) on investment in equity securities 0.18 (0.02 ) 0.10 (0.01 )
Acquisition, integration and divestiture-related items 0.69 0.52 0.75 0.91
Other (0.01 ) (0.00 ) 0.49 (0.04 )
Income tax effect of non-GAAP adjustments(a) (0.56 ) (0.25 ) (0.74 ) (0.74 )
Adjusted net income per share - diluted(b) $ 1.68 $ 1.27 $ 4.70 $ 4.43
Weighted-average common shares outstanding - diluted 68,413 67,663 67,137 69,038

(a) Represents the estimated income tax effect of the adjustments between GAAP net income and adjusted net income (non-GAAP).
(b) Amounts may not add due to rounding.

Lantheus Holdings, Inc. Reconciliation of GAAP to Non-GAAP Financial Measures (Continued) (in thousands, except per share and percent data – unaudited)
Three Months Ended September 30, Nine Months Ended September 30,
2026 2025 2026 2025
Operating income $ 32,206 $ 43,615 $ 213,747 $ 233,648
Stock and incentive plan compensation 21,876 24,501 57,925 68,020
Amortization of acquired intangible assets 16,723 14,639 50,169 30,626
Impairment of intangible assets 31,000 — 31,000 —
Contingent consideration fair value adjustments 3,169 982 (28,586 ) 982
Non-recurring fees 7 — 9,292 2,633
Strategic collaboration and license costs 32 860 269 16,273
Acquisition, integration and divestiture-related items 46,175 34,973 55,404 62,645
Other 2,011 (16 ) 35,142 1,557
Adjusted operating income $ 153,199 $ 119,554 $ 424,362 $ 416,384
Adjusted operating income, as a percentage of revenues 39.3 % 31.1 % 36.7 % 36.7 %
Lantheus Holdings, Inc. Reconciliation of Free Cash Flow (in thousands – unaudited)
Three Months Ended September 30, Nine Months Ended September 30,
2026 2025 2026 2025
Net cash provided by operating activities $ 101,974 $ 105,294 $ 319,304 $ 299,963
Capital expenditures (2,046 ) (10,622 ) (7,607 ) (27,301 )
Free cash flow $ 99,928 $ 94,672 $ 311,697 $ 272,662
Net cash (used in) provided by investing activities $ (11,135 ) $ (319,468 ) $ 12,828 $ (615,658 )
Net cash used in financing activities $ (460 ) $ (99,166 ) $ (7,578 ) $ (215,798 )
Lantheus Holdings, Inc. Condensed Consolidated Balance Sheets (in thousands – unaudited)
September 30, December 31,
2026 2025
Assets
Current assets:
Cash and cash equivalents $ 683,610 $ 359,121
Accounts receivable, net 345,684 358,640
Inventory, net 64,212 64,674
Income tax receivable — 15,387
Other current assets 30,204 21,400
Assets held for sale — 80,742
Total current assets 1,123,710 899,964
Investment in equity securities 98,427 42,213
Long-term notes receivable 25,297 —
Property, plant and equipment, net 149,627 163,686
Intangibles, net 641,612 722,779
Goodwill 238,626 239,517
Deferred tax assets, net 121,135 109,196
Other long-term assets 57,699 50,044
Total assets $ 2,456,133 $ 2,227,399
Liabilities and Stockholders’ Equity
Current liabilities:
Current portion of long-term debt and other borrowings $ 605 $ 738
Accounts payable 47,700 42,906
Accrued expenses and other current liabilities 297,662 267,307
Liabilities held for sale — 22,468
Total current liabilities 345,967 333,419
Asset retirement obligations 257 138
Long-term debt and other borrowings, net of current portion 571,136 568,678
Long-term deferred tax liabilities 41,136 54,246
Long-term contingent consideration liabilities, net of current portion 51,657 73,255
Other long-term liabilities 90,268 107,866
Total liabilities 1,100,421 1,137,602
Total stockholders’ equity 1,355,712 1,089,797
Total liabilities and stockholders’ equity $ 2,456,133 $ 2,227,399

**


Nov 5, 2026

PDF Version

Final rule maintains separate payment for advanced diagnostic imaging agents and confirms PYLARIFY TruVu™ Transitional Pass-Through status through September 30, 2029; permanent HCPCS code A9613 now in effect

BEDFORD, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today welcomed the Centers for Medicare & Medicaid Services' (CMS) Calendar Year 2027 Hospital Outpatient Prospective Payment System (OPPS) final rule, which maintains separate payment for qualifying diagnostic radiopharmaceuticals. CMS also confirmed PYLARIFY TruVu (piflufolastat F 18) injection will receive Transitional Pass-Through (TPT) payment status through September 30, 2029, reflecting the full three-year TPT period available in the hospital outpatient setting. PYLARIFY TruVu has also been assigned permanent Healthcare Common Procedure Coding System (HCPCS) code A9613, effective October 1, 2026, facilitating billing and reimbursement for providers.

"The CMS final rule represents an important step in supporting patient access to advanced diagnostic imaging and the adoption of innovative radiopharmaceutical technologies," said Amanda Morgan, Chief Commercial Officer of Lantheus. “CMS’ confirmation that PYLARIFY TruVu will receive Transitional Pass-Through status for the full three-year period through September 30, 2029, together with its permanent HCPCS code, provides additional reimbursement certainty for hospitals while helping ensure patients can benefit from PSMA PET imaging to inform their prostate cancer care. Continued separate payment for diagnostic radiopharmaceuticals recognizes the important role advanced imaging plays in guiding treatment decisions and supporting patient care.”

Lantheus' commercial radiodiagnostic portfolio includes PYLARIFY®, PYLARIFY TruVu and NEURACEQ® (florbetaben F 18), alongside a broad pipeline of diagnostic radiopharmaceutical candidates across oncology, neurology and cardiology. The Company continues to support policies that enable appropriate reimbursement and patient access as new diagnostic radiopharmaceuticals reach clinical practice.

PYLARIFY TruVu (piflufolastat F 18) Injection

INDICATION 
PYLARIFY® (piflufolastat F 18) and PYLARIFY TRUVUTM (piflufolastat F 18) Injection are indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer: 

  • with suspected metastasis who are candidates for initial definitive therapy. 
  • with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level. 

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS 
Risk of Image Misinterpretation 
Imaging interpretation errors can occur with PYLARIFY and PYLARIFY TRUVU imaging. A negative image does not rule out the presence of prostate cancer and a positive image does not confirm the presence of prostate cancer. The performance of PYLARIFY and PYLARIFY TRUVU for imaging biochemical evidence of recurrence of prostate cancer seems to be affected by serum PSA levels. The performance of PYLARIFY and PYLARIFY TRUVU for imaging of metastatic pelvic lymph nodes prior to initial definitive therapy seems to be affected by risk factors such as Gleason score and tumor stage. PYLARIFY and PYLARIFY TRUVU uptake is not specific for prostate cancer and may occur with other types of cancer as well as non-malignant processes and in normal tissues. Clinical correlation, which may include histopathological evaluation, is recommended. 

Hypersensitivity Reactions  
Monitor patients for hypersensitivity reactions, particularly those with a history of allergy to other drugs and foods. Reactions may be delayed. Always have trained staff and resuscitation equipment available. 

Radiation Risks 
PYLARIFY and PYLARIFY TRUVU, expose patients to radiation. Radiation exposure is associated with a dose-dependent increased risk of cancer. Ensure safe handling and preparation procedures to protect patients and health care workers from unintentional radiation exposure. Advise patients to hydrate before and after administration and to void frequently after administration.

ADVERSE REACTIONS 
The most frequently reported adverse reactions were headaches, dysgeusia and fatigue, occurring at rate of ≤2% during clinical studies. In addition, a delayed hypersensitivity reaction was reported in one patient (0.2%) with a history of allergic reactions. 

DRUG INTERACTIONS 
Androgen deprivation therapy (ADT) and other therapies targeting the androgen pathway, such as androgen receptor antagonists, may result in changes in uptake of PYLARIFY and PYLARIFY TRUVU in prostate cancer. The effect of these therapies on performance of PYLARIFY and PYLARIFY TRUVU PET has not been established. 
 
To report suspected adverse reactions for PYLARIFY or PYLARIFY TRUVU, call 1-800-362-2668 or contact FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . Please see the full Prescribing Information for PYLARIFY and PYLARIFY TRUVU .

Safe Harbor for Forward-Looking and Cautionary Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that are subject to risks and uncertainties and are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by their use of terms such as “believe,” “continue,” “efforts,” “enables,” “expand,” “improved,” and other similar terms. Such forward-looking statements are based upon current plans, estimates and expectations that are subject to risks and uncertainties that could cause actual results to materially differ from those described in the forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation that such plans, estimates and expectations will be achieved. Readers are cautioned not to place undue reliance on the forward-looking statements contained herein, which speak only as of the date hereof. Lantheus undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law. Risks and uncertainties that could cause our actual results to materially differ from those described in the forward-looking statements include (i) our ability to complete the technology transfer across our PET manufacturing facilities (“PMF”) network for PYLARIFY TruVu and to obtain FDA approval for each PMF to manufacture PYLARIFY TruVu in accordance with our planned rollout plan and without disruption to our supply chain; (ii) our ability to have payers add HCPCS coding to their systems on a timely basis and to have customers adopt PYLARIFY TruVu; (iii) the ability of our PMF network to supply PYLARIFY TruVu to the market; (iv) the ability of PMF sites with high‑energy cyclotrons to increase batch sizes or to reach more patients and serve broader geographic markets; (v) the intellectual property protection of PYLARIFY TruVu; and (vi) the risk and uncertainties discussed in our filings with the Securities and Exchange Commission (including those described in the Risk Factors section in our Annual Reports on Form 10-K and our Quarterly Reports on Form 10-Q).

About Lantheus
Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices in New Jersey, Canada, Germany, Sweden, Switzerland and the United Kingdom, Lantheus has been providing radiopharmaceutical solutions for 70 years. For more information, visit www.lantheus.com .

Prompts

Lantheus Holdings, Inc. (ticker LNTH), listed in United States.

Company History

Date Change Detail
Apr 17, 2014 Renamed Lantheus MI Holdings, Inc. → LANTHEUS HOLDINGS, INC.

ETFs Holding Lantheus Holdings, Inc.

ETF Weight in ETF Shares Market value As of
ZIG 3.33% 10,321 $ 1.051M Nov 18, 2026
IVSS 1.25% 3,032 $ 336.37K Jun 30, 2026
JSML 1.16% 42,161 $ 4.201M Jul 31, 2026
EVNT 0.98% 1,275 $ 128.724K Aug 31, 2026
JSMD 0.92% 97,293 $ 9.694M Jul 31, 2026
HWSM 0.71% 177 $ 19.636K Jun 30, 2026
FFSM 0.61% 91,602 $ 9.127M Jul 31, 2026
NDOW 0.61% 3,809 $ 422.57K Jun 30, 2026
LITL 0.58% 326 $ 33.187K Nov 17, 2026
FTKI 0.54% 1,352 $ 137.525K Nov 16, 2026
AVUV 0.43% 1,361,120 $ 138.453M Nov 16, 2026
PSC 0.39% 82,706 $ 9.175M Jun 30, 2026
SEIS 0.34% 17,631 $ 1.956M Jun 30, 2026
RESM 0.32% 107 $ 11.871K Jun 30, 2026
SMDX 0.28% 3,521 $ 358.156K Nov 17, 2026
RUSC 0.25% 1,781 $ 197.584K Jun 30, 2026
TMSL 0.23% 57,017 $ 6.325M Jun 30, 2026
SAGP 0.22% 1,491 $ 165.412K Jun 30, 2026
JMEE 0.20% 57,156 $ 5.818M Nov 17, 2026
SCDS 0.11% 103 $ 10.485K Nov 17, 2026
AVSU 0.06% 2,897 $ 294.683K Nov 16, 2026
MSSM 0.05% 3,302 $ 333.37K Aug 31, 2026
MPLY 0.02% 31 $ 3,088.84 Jul 31, 2026
DFSU 0.01% 2,896 $ 293.22K Nov 12, 2026
AVUS 0.01% 8,141 $ 828.103K Nov 16, 2026
AVUQ 0.01% 225 $ 22.887K Nov 16, 2026
DFUV 0.01% 8,261 $ 836.426K Nov 12, 2026
DFAC 0.00% 23,898 $ 2.42M Nov 12, 2026
DXUV 0.00% 807 $ 81.709K Nov 12, 2026
DCOR 0.00% 2,082 $ 210.803K Nov 12, 2026
FSCC 0.00% 2 $ 201.92 Aug 31, 2026
AVLV 0.00% 7,361 $ 748.761K Nov 16, 2026